



PUBBLICAZIONI 2015

<p>Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.</p> <p>[Nat Commun. 2015 December 23; 5: 5699]</p> <p>Terczyńska-Dyla E • Bilbert S • Duong FH • Krol I • Jørgensen S • Collinet E • Kotalik Z • Aubert V • Cerny A • Kaiser L • Malinverni R • Mangia A • Moradpour D • Müllhaupt B • Negro F • Santoro R • Semela D • Semmo N • Swiss Hepatitis C Cohort Study Group • Heim MH • Bochud PY • Hartmann R.</p>
<p>A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus Clearance.</p> <p>[Hepatology. November 2015; v62(5): 1375-87]</p> <p>Wang H • El Maadidi S • Fischer J • Grabski E • Dickhöfer S • Klimosch S • Flannery SM • Filomena A • Wolz OO • Schneider-Marra N • Löffler MW • Wiese M • Pichulk T • Müllhaupt B • Semela D • Dufour JF • Bochud PY • Bowie AG • Kalinke U • Berg T • Weber AN • East-German and Swiss Hepatitis C Virus Study Groups.</p>
<p>O077: use of direct oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and/or cirrhosis.</p> <p>[Journal of Hepatology 2015; 62, suppl 2: S229]</p> <p>De Gottardi A • Seijo S • Plessier A • Schouten J • Trebicka J • Terziroli Beretta-Piccoli B • Magenta L • Semela D • Langlet P • Turon F • Arya R • Peck-Radosavljevic M • Valla D • Garcia-Pagan JC.</p>
<p>Impact of common risk factors of fibrosis progression in chronic Hepatitis C.</p> <p>[Gut. October 2015; 64(10):1605-15]</p> <p>Rüeger S • Bochud PY • Dufour JF • Müllhaupt B • Semela D • Heim MH • Moradpour D • Cerny A • Malinverni R • Booth DR • Suppiah V • George J • Argiro L • Halfon P • Bourlière M • Talal AH • Jacobson IM • Patin E • Nalpas B • Poynard T • Pol S • Abel L • Kotalik Z • Negro F.</p>
<p>Telaprevir-induced renal impairment: three clinical cases and a review of the literature.</p> <p>[Infect Dis (Lond). September 2015; 47(9): 662-7]</p> <p>Andreocchi L • Toma V • Canonica-Lepori A • Magenta L • Györik S • Pellegrini L • Bernasconi E.</p>
<p>Screening for liver cancer in high risk patients in Switzerland: Yes, it works, but No, we do not do it systematically!</p> <p>[Swiss Med Wkly. 2015 December 23; 145:w 14231. doi: 10.4414 / smw. 2015. 14231. eCollection 2015]</p> <p>Cerny A.</p>
<p>Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.</p> <p>[Nat Commun. 2015 June 29;6:7280]</p> <p>Terczyńska-Dyla E • Bilbert S • Duong FH • Krol I • Jørgensen S • Collinet E • Kotalik Z • Aubert V • Cerny A • Kaiser L • Malinverni R • Mangia A • Moradpour D • Müllhaupt B • Negro F • Santoro R • Semela D • Semmo N. Swiss Hepatitis C Cohort Study Group • Heim MH • Bochud PY • Hartmann R.</p>
<p>Update chronische Hepatitis B und C.</p> <p>[Praxis 2015; 104:1393-7]</p> <p>Terziroli Beretta-Piccoli B • Schranz M • De Gottardi A • Cerny A.</p>
<p>Malattie Epatiche.</p> <p>[Monografia Tribuna Medica Ticinese. Maggio 2015; 5]</p> <p>Cerny A • Schranz M • Magenta L • Monotti R • Hagara D • Gurtner V • Balmelli M • Schwarzenbach HR • Moriggia A • Terziroli Beretta-Piccoli B • Mazzucchelli L.</p>



Fondazione
Epatocentro Ticino

Epatopatia alcolica.

[Tribuna Medica Ticinese. Luglio/Agosto 2015; 7/8]

Robatto A • Moriggia A.

Una donna in menopausa con transaminasi elevate.

[Tribuna Medica Ticinese. Maggio 2015; 5: 125-132]

Terzioli Beretta-Piccoli B • Mazzucchelli L.